These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 657108

  • 61. Granulomatous eruption after BCG vaccine immunotherapy for malignant melanoma.
    Shea CR, Imber MJ, Cropley TG, Cosimi AB, Sober AJ.
    J Am Acad Dermatol; 1989 Nov; 21(5 Pt 2):1119-22. PubMed ID: 2681298
    [Abstract] [Full Text] [Related]

  • 62. Demonstration of lymphocyte blastogenesis--inhibiting factors in sera of melanoma patients.
    Rangel DM, Golub SH, Morton DL.
    Surgery; 1977 Aug; 82(2):224-32. PubMed ID: 877866
    [Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64. [Local immunotherapy. Alternative therapy for malignant cutaneous lesions (demonstration on 30 patients with malignant melanoma) (author's transl)].
    Kokoschka EM, Micksche M.
    Wien Klin Wochenschr; 1979 Mar 02; 91(5):150-4. PubMed ID: 425533
    [Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66. Risks of BCG intralesional therapy: an experience with melanoma.
    Robinson JC.
    J Surg Oncol; 1977 Mar 02; 9(6):587-93. PubMed ID: 145518
    [Abstract] [Full Text] [Related]

  • 67. Immunotherapy of malignant melanoma.
    Thiers BH.
    J Am Acad Dermatol; 1982 Apr 02; 6(4 Pt 1):559-62. PubMed ID: 6176602
    [No Abstract] [Full Text] [Related]

  • 68. Immunopathologic changes in patients with cutaneous malignant melanoma following intratumoral inoculation BCG: correlation with cell-mediated immunity.
    Lieberman R, Epstein W, Fudenberg HH.
    Int J Cancer; 1974 Sep 15; 14(3):401-16. PubMed ID: 4617711
    [No Abstract] [Full Text] [Related]

  • 69. Dinitrochlorobenzene skin sensitization and peripheral lymphocyte count: predictors of survival in head and neck cancer.
    Maisel RH, Ogura JH.
    Ann Otol Rhinol Laryngol; 1976 Sep 15; 85(4 Pt 1):517-22. PubMed ID: 949158
    [Abstract] [Full Text] [Related]

  • 70. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
    Berd D, Mastrangelo MJ.
    Cancer Invest; 1988 Sep 15; 6(3):337-49. PubMed ID: 3167614
    [Abstract] [Full Text] [Related]

  • 71. Combined immunotherapy in malignant melanoma. Regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and Bacillus Calmette-Guérin.
    Spitler LE, Levin AS, Wybran J.
    Cell Immunol; 1976 Jan 15; 21(1):1-19. PubMed ID: 764975
    [No Abstract] [Full Text] [Related]

  • 72. Intralesional BCG application in malignant melanoma.
    Sopková B, Kolár V.
    Neoplasma; 1976 Jan 15; 23(4):421-6. PubMed ID: 794745
    [Abstract] [Full Text] [Related]

  • 73. Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer.
    Wile AG, Sparks FC, Morton DL.
    Cancer Res; 1977 Jul 15; 37(7 Pt 1):2251-6. PubMed ID: 324610
    [Abstract] [Full Text] [Related]

  • 74. [Treatment of malignant melanoma with dinitrochlorobenzene ointment].
    Loth H, Ehring F.
    Hautarzt; 1978 Mar 15; 29(3):141-6. PubMed ID: 640834
    [Abstract] [Full Text] [Related]

  • 75. Generalized urticaria from DNCB.
    Valsecchi R, Foiadelli L, Reseghetti A, Cainelli T.
    Contact Dermatitis; 1986 Apr 15; 14(4):254-5. PubMed ID: 2941231
    [No Abstract] [Full Text] [Related]

  • 76. [Cross allergies following sensitization with dinitrochlorbenzol (DNCB)].
    Djawari D, Körner E, Haneke E.
    Hautarzt; 1980 Apr 15; 31(4):198-202. PubMed ID: 7399912
    [Abstract] [Full Text] [Related]

  • 77. [Decrease in immunoreactivity in melanoma. Analysis of DNCB tests in the literature].
    Remy W, Dorn R, Ulm K, Mayerhausen W.
    Z Hautkr; 1986 Dec 15; 61(24):1767-77. PubMed ID: 3825218
    [Abstract] [Full Text] [Related]

  • 78. Treatment of lung cancer by radiotherapy, chemotherapy, and methanol extraction residue of BCG (MER): clinical and immunological studies.
    Robinson E, Bartal A, Cohen Y, Haasz R, Mekori T.
    Cancer; 1977 Sep 15; 40(3):1052-9. PubMed ID: 902232
    [Abstract] [Full Text] [Related]

  • 79. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.
    Gutterman JU, Mavligit G, Gottlieb JA, Burgess MA, McBride CE, Einhorn L, Freireich EJ, Hersh EM.
    N Engl J Med; 1974 Sep 19; 291(12):592-7. PubMed ID: 4851001
    [No Abstract] [Full Text] [Related]

  • 80. Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma.
    Kidner TB, Morton DL, Lee DJ, Hoban M, Foshag LJ, Turner RR, Faries MB.
    J Immunother; 2012 Sep 19; 35(9):716-20. PubMed ID: 23090081
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.